Trials / Active Not Recruiting
Active Not RecruitingNCT02477696
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 533 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acalabrutinib | Participants will receive oral acalabrutinib as stated in arm description. |
| DRUG | Ibrutinib | Participants will receive oral ibrutinib as stated in arm description. |
Timeline
- Start date
- 2015-07-28
- Primary completion
- 2020-09-15
- Completion
- 2028-01-03
- First posted
- 2015-06-23
- Last updated
- 2026-03-27
- Results posted
- 2022-01-28
Locations
130 sites across 15 countries: United States, Australia, Belgium, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02477696. Inclusion in this directory is not an endorsement.